High-throughput screening for analysis of in vitro toxicity

Area of Science:

• Pharmacology and Toxicology
• Drug Discovery and Development
• Biotechnology

Background:

• Combinatorial chemistry and high-throughput screening (HTS) have significantly impacted drug discovery.
• Despite technological advances, drug attrition rates in clinical trials due to toxicity remain high (40-50%).
• There is a critical need for early toxicity screening assays to mitigate late-stage failures.

Purpose of the Study:

• To provide a comprehensive overview of current early toxicity screening assays.
• To highlight advancements in genotoxicity, cytotoxicity, carcinogenicity, and reprotoxicity testing.
• To discuss methods for analyzing enzyme induction and receptor-mediated effects.

Main Methods:

• Review of established and novel assays for various toxicity endpoints.
• Discussion of genotoxicity assays including Ames, Ames II, Vitotox, GreenScreen GC, and RadarScreen.
• Description of cytotoxicity assays measuring cellular proliferation, mitochondrial activity, and apoptosis.
• Examination of high-content screening (HCS) for cytotoxicity and genotoxicity.
• Overview of alternative assays for embryotoxicity, endocrine disruption, and reprotoxicity using nuclear and membrane receptors.
• Methods for analyzing enzyme induction via nuclear receptor activation (AhR, CAR, PXR, PPAR, FXR, LXR, TR, RAR).

Main Results:

• Detailed descriptions of multiple assays for assessing genotoxicity, cytotoxicity, and carcinogenicity.
• Exploration of HCS capabilities for analyzing cellular damage and specific toxicities.
• Presentation of alternative assays for rapid assessment of reproductive and developmental toxicity.
• Solutions for evaluating enzyme induction by various nuclear receptors are provided.

Conclusions:

• The development and application of diverse early toxicity screening assays are essential for improving drug safety and reducing clinical attrition.
• State-of-the-art assays offer enhanced capabilities for predicting potential drug toxicities.
• These assays facilitate faster and more reliable drug development pipelines.